School of Medicine, Bam University of Medical Sciences, Bam, Iran.
Student Research Committee, Bam University of Medical Sciences, Bam, Iran.
IUBMB Life. 2021 Apr;73(4):659-669. doi: 10.1002/iub.2458. Epub 2021 Mar 3.
One of the most common malignant tumors is hepatocellular carcinoma (HCC). Progression of HCC mainly results from highly complex molecular and pathological pathways. Midkine (MDK) is a growth factor that impacts viability, migration, and other cell activities. Since MDK has been involved in the inflammatory responses, it has been claimed that MDK has a crucial role in HCC. MDK acts as an anti-apoptotic factor, which mediates tumor cell viability. In addition, MDK blocks anoikis to promote metastasis. There is also evidence that MDK is involved in angiogenesis. It has been shown that the application of anti-MDK approaches might be promising in the treatment of HCC. Besides, due to the elevated expression in HCC, MDK has been proposed as a biomarker in the prognosis and diagnosis of HCC. In this review, we will discuss the role of MDK in HCC. It is hoped that the development of new strategies concerning MDK-based therapies will be promising in HCC management.
最常见的恶性肿瘤之一是肝细胞癌 (HCC)。HCC 的进展主要源于高度复杂的分子和病理途径。中期因子 (MDK) 是一种影响活力、迁移和其他细胞活动的生长因子。由于 MDK 参与了炎症反应，因此有人声称 MDK 在 HCC 中起着关键作用。MDK 作为一种抗细胞凋亡因子，介导肿瘤细胞活力。此外，MDK 阻止失巢凋亡以促进转移。还有证据表明 MDK 参与血管生成。已经表明，应用抗 MDK 方法可能在 HCC 的治疗中有很大的潜力。此外，由于在 HCC 中表达升高，MDK 已被提议作为 HCC 预后和诊断的生物标志物。在这篇综述中，我们将讨论 MDK 在 HCC 中的作用。希望基于 MDK 的治疗的新策略的发展在 HCC 管理中是有前景的。
